Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-Resistant Recurrent Ovarian Cancer

Summary by The Daily News
RAHWAY, N.J.--(BUSINESS WIRE)--Oct 18, 2025-

1 Articles

The Daily NewsThe Daily News
Center

KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-Resistant Recurrent Ovarian Cancer

RAHWAY, N.J.--(BUSINESS WIRE)--Oct 18, 2025-

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

The Daily News broke the news in on Saturday, October 18, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Rahway icon

Rahway

News
For You
SearchBlindspotLocal